Suboxone vs Naltrexone vs Methadone: How the Choice Is Made

Suboxone (buprenorphine with naloxone), naltrexone and methadone are the three medicines used for opioid use disorder, and they work in opposite ways: buprenorphine partly activates opioid receptors, methadone fully activates them, and naltrexone blocks them entirely. No single option is best for everyone; the right choice depends on tolerance, stability and circumstances.

You may have arrived at this question from either side of it. Perhaps you are the person facing the decision, having read that there are options and wondering why anyone would choose a blocker over a stabiliser, or a daily clinic visit over a tablet you can take at home. Or perhaps you are a parent, a partner or a sibling who has just been told a clinician is recommending one medication rather than another for someone you love, and you want to understand the reasoning rather than simply accept it.

Both of you deserve a straight answer. The three medicines are not interchangeable, and the differences between them are not marketing — they are pharmacological and practical, and they change who each one suits. What follows is a comparison, not another explanation of each drug from scratch. We have written separately and in depth about each medication, and this piece is about the decision that sits above them.

What is the core difference between Suboxone, naltrexone and methadone?

The three medicines act on the same opioid receptors but do opposite things at them. Methadone fully activates the receptor, buprenorphine partly activates it, and naltrexone blocks it altogether.

The U.S. Food and Drug Administration classifies the three approved medications by exactly this mechanism: methadone is a full mu-opioid agonist, buprenorphine (the active medicine in Suboxone) is a partial agonist, and naltrexone is an antagonist. A full agonist keeps producing more effect as the dose rises. A partial agonist has a built-in ceiling that limits how far that effect can climb, which is what makes buprenorphine comparatively safer in overdose. An antagonist produces no opioid effect at all; it simply occupies the receptor so that other opioids cannot reach it. If you want the full picture of any one of them, our in-depth guide to Suboxone and our explanation of how naltrexone works in detail cover each medication on its own. This article assumes that groundwork and focuses on how they compare.

Which medication fits which clinical situation?

Broadly, methadone suits high tolerance and a long, entrenched history; buprenorphine suits most people needing a safer, more flexible stabiliser; and naltrexone suits someone already through withdrawal who wants no agonist at all.

These are tendencies, not rules. Methadone, as a full agonist without a ceiling, can hold a person with very heavy, long-standing opioid use whom a partial agonist may not fully cover, and it has the longest track record and the largest evidence base of the three. Buprenorphine is the middle path for a great many people: it quiets withdrawal and cravings, its ceiling lowers overdose risk, and it can be managed in more settings than methadone. Naltrexone is different in kind — it treats nobody’s withdrawal, because it is a blocker rather than a stabiliser. It suits a person who has already completed detox and is committed to an opioid-free approach, sometimes including those who prefer or are required to take no agonist medication at all. The catch, covered below, is that getting a person onto naltrexone is the hardest of the three.

For a family member trying to make sense of a recommendation, it can help to hold on to one idea: the clinician is not reaching for the strongest medicine or the most convenient one, but the one whose profile best matches the person in front of them. Someone with a decade of high-dose use and several stalled attempts at abstinence is a different clinical problem from someone who has used for months and is frightened of dependence on any opioid at all, and the same medication rarely answers both.

How do the three compare on keeping people in treatment?

Staying in treatment is one of the strongest predictors of survival, and on retention the evidence separates the three. Methadone tends to keep the most people in care, buprenorphine somewhat fewer, and naltrexone fewer again.

A 2022 network meta-analysis of randomised trials in PLOS ONE found average retention rates of 64.1% for methadone, 54.3% for buprenorphine and 41.0% for naltrexone. In head-to-head terms, methadone was more likely to retain patients than buprenorphine (relative risk 1.22) and than naltrexone (1.69), and buprenorphine more likely than naltrexone (1.39). This matters, but it is easy to read badly. Higher retention does not make methadone the automatic winner for any individual, because much of naltrexone’s lower figure reflects the difficulty of getting people started on it at all, not a failure of the medicine once it is on board. Retention is a measure of the whole treatment experience — access, tolerability, structure — not simply of a drug’s strength.

Why is naltrexone so much harder to start than the others?

Because naltrexone is a pure blocker, a person has to be fully off opioids before the first dose, or it triggers immediate, severe withdrawal. Clearing that hurdle is where many people fall away.

The clearest demonstration is the X:BOT trial published in The Lancet, which compared extended-release naltrexone against buprenorphine-naloxone. Twenty-eight per cent of those assigned to naltrexone could not even initiate the medication, against just 6% assigned to buprenorphine-naloxone. Once people were successfully started, the two performed similarly — but the initiation gap meant that, counting everyone from the point of assignment, the buprenorphine-naloxone group had fewer relapse events. The lesson is practical rather than damning: naltrexone can work well, but it requires a completed, medically managed withdrawal first, which is far easier to achieve in a supervised residential setting than at home.

How do access and regulation differ between them?

The three medicines are governed very differently, and that shapes real-world choice as much as pharmacology does. Methadone is the most tightly controlled, buprenorphine the most flexible, and naltrexone gated mainly by the need to detox first.

The FDA notes that methadone for opioid use disorder can only be dispensed through registered Opioid Treatment Programs, which in practice means attending a clinic, often daily, to receive each dose. Buprenorphine can be prescribed by a much wider range of clinicians and, in many places, managed by telehealth, giving it far more flexibility. Naltrexone can be given by any appropriate provider, and only its extended-release injectable form is indicated for OUD, but its real barrier is the opioid-free interval it demands beforehand. These regulatory details vary between countries and are framed here around the well-documented US system; the underlying pattern of one medicine tightly dispensed, one flexible, and one gated by detox holds broadly. Within a residential programme, much of this changes shape, because assessment, induction and daily supervision all happen on-site rather than being spread across separate clinics and prescribers.

How Holina Rehab chooses the right medication

At our residential campus on the beachfront of Koh Phangan, the choice between these medicines is never made from a leaflet or a preference stated on arrival. It begins with a medically supervised assessment that looks at a person’s tolerance, opioid history, physical health, any co-occurring behavioural health difficulties and what has been tried before. Because induction happens on-site under direct medical supervision, options that are difficult to start safely elsewhere become genuinely available here — a completed, observed detox can open the door to naltrexone for a suitable person, while buprenorphine induction can be timed precisely rather than guessed at alone.

Whichever medication is selected, it sits inside our Dual Treatment programme, delivered across 30, 60 and 90-day tiers so the depth of care matches what each person is actually working through. The medicine steadies withdrawal and craving; the therapy addresses what sits beneath the substance use. Our clinical team, led by Dr. Natalie Lindemann as Clinical Director, reviews each person individually and revisits the decision as they stabilise, because the right medication at intake is not always the right one three weeks in.

“Families often ask me why we chose one medication over another, as though there were a single correct answer we simply looked up. There is not. The question is always which medicine fits this person — their tolerance, their history, their readiness — and how it will work alongside the therapy. Methadone, buprenorphine and naltrexone are not ranked from best to worst. They are different tools, and the skill is in matching, not ranking.” — Dr. Natalie Lindemann, Clinical Director (Global), Holina Global

Frequently asked questions

Which medication is the best for opioid use disorder?

There is no single best option. Methadone, buprenorphine and naltrexone each suit different people depending on tolerance, opioid history, stability and circumstances, and the right choice is a clinical decision made with the individual.

Is Suboxone the same as buprenorphine?

Suboxone is a brand-name combination of buprenorphine, the active medicine, and naloxone, added to deter misuse. When people compare Suboxone with methadone or naltrexone, buprenorphine is the ingredient doing the therapeutic work.

Why would a clinician recommend naltrexone if it keeps fewer people in treatment on average?

Because much of that lower retention reflects the difficulty of starting naltrexone rather than the medicine failing once begun. For a person who has already completed detox and wants no agonist, it can be a good fit, especially with supervised initiation.

Is methadone stronger than Suboxone?

Methadone is a full agonist without a ceiling effect, so it can suit someone with very high, long-standing tolerance whom a partial agonist may not fully cover. That strength is also why it is dispensed under tighter controls.

Why is naltrexone so hard to start?

Naltrexone blocks opioid receptors, so a person must be fully off opioids first or it triggers immediate, severe withdrawal. This is far easier to manage safely within a supervised residential detox than at home.

Can you switch between these medications?

Yes, though switching must be done carefully and under supervision, because moving between an agonist, a partial agonist and a blocker involves specific timing to avoid precipitated withdrawal. The plan is often revisited as a person stabilises.

Do all three medications require therapy as well?

Effective treatment pairs medication with therapy in every case. The medicine steadies the body; therapy addresses the reasons a person began using. Holina delivers both together through the Dual Treatment programme.

Which medication is safest in overdose terms?

Buprenorphine’s partial-agonist ceiling limits respiratory depression, giving it a comparatively safer profile than full-agonist methadone. Naltrexone produces no opioid effect at all, but that is a different matter from stabilising someone in active use.

Is one of these medications better for a loved one who has relapsed several times?

Not automatically. Repeated relapse prompts a fresh assessment of tolerance, what was tried before and why it did not hold, rather than a fixed switch to a particular drug. That review is exactly what our clinical team carries out.

Does the choice of medication depend on how long someone has been using?

It is one of several factors. A long, heavy history may point towards methadone, while a shorter or less severe pattern may be well served by buprenorphine, and a person already through withdrawal may consider naltrexone. Tolerance and overall health matter alongside duration.

Can these medications be started at home?

Some can be initiated in outpatient settings, but induction is safest under clinical observation, and naltrexone in particular requires a completed detox first. Residential care removes the timing risks of starting alone.

How do I discuss these options for myself or a family member?

You can speak with our admissions team about an assessment, and there is dedicated support for families trying to understand a clinician’s recommendation for someone they love.

Clinically reviewed by Dr. Natalie Lindemann — Clinical Director, Holina Global · Last reviewed 20 July 2026.